To investigate, we compared the gene composition of melanoma cells treated with CDK4/6 and PRMT5 inhibitors using PCA, which revealed each treatment reproducibly results in distinct expression profiles across the two cell lines [Fig 2A and 2B]. Here, PRMT5 is linked to melanoma.